The Digital Therapeutics Alliance defines a digital therapeutic (DTx) as “evidence-based therapeutic interventions which are pushed by high-quality software program packages to forestall, handle, or deal with a medical dysfunction or illness.” One key query is what elements do US payers consider when evaluating DTx and the way does that differ from customary prescribed drugs. A paper by Gomez Lumbreras et al. (2024) held digital focus teams with 21 US payers to search out the reply. Key concerns embrace:
- Want for Proof. Nearly all survey respondents (n = 19/21 90%) indicated they’d require a scientific trial to contemplate protection of the product. This proof contains knowledge on efficacy, effectiveness and worth (together with cost-effectiveness perspective)
- DTx Protection: Medical, Pharmacy or Different? Many respondents have been unsure if reimbursement ought to undergo medical or pharmacy advantages. The bulk thought it could in all probability be the pharmacy and therapeutics committee (n = 15/21 71%), however , a number of members answered “different” (n = 6/21, 29%) [see Figure below]
- FDA Regulation and Pending Laws. General, 14/21 (66.7%) respondents would require an FDA analysis of the DTx product for it to be thought of for protection (particularly if coated underneath the pharmacy profit). Different respondents indicated that FDA analysis was helpful however not at all times required for protection. A number of payers cited the necessity for proof past the necessities of the FDA to contemplate a DTx product for protection (e.g., effeciveness, worth).
- Reimbursement: NDC vs. CPT. A prescription can be mandatory for a lot of well being plans to reimburse a DTx product on condition that many insurance policies exclude reimbursement for over-the-counter merchandise. Members extensively agreed {that a} coding system can be required, and {that a} Present Procedural Terminology (CPT) code or Nationwide Drug Code (NDC) can be probably the most environment friendly methods to make sure reimbursement.
- Obstacles. Obstacles talked about embrace sturdiness of therapy impact, value of merchandise, and mechanisms for reimbursement/cost. Different points included the position of DTx merchandise on affected person engagement and therapy adherence. Many perceived that DTx weren’t “bona fide” therapies partially as a result of some thought of them simply “apps” and comparable variations might be downloaded on-line at no cost.
- Payer Administration. Some claimed that utilization administration insurance policies (e..g, prior authorization, step edits, amount limits) might be used for DTx simply as they’re for pharmaceuticals. Others instructed {that a} DTx product might be a part of a care administration program reasonably than overlaying it individually. Just a few members defined that their organizations have been at present overlaying DTx merchandise as a part of scientific packages.
You’ll be able to learn the total article with useful quotations right here.